Tevogen Bio (NASDAQ:TVGN) Trading Up 4.4% – Here’s Why

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shares were up 4.4% during trading on Tuesday . The company traded as high as $4.16 and last traded at $4.06. Approximately 17,177 shares traded hands during mid-day trading, a decline of 20% from the average daily volume of 21,579 shares. The stock had previously closed at $3.89.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a report on Friday. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $100.00.

Tevogen Bio Price Performance

The firm’s 50 day moving average is $7.97 and its 200 day moving average is $9.68. The company has a market capitalization of $17.00 million, a PE ratio of -0.88 and a beta of 0.20.

Tevogen Bio (NASDAQ:TVGN) last posted its quarterly earnings results on Friday, May 15th. The company reported ($1.61) EPS for the quarter, beating analysts’ consensus estimates of ($2.64) by $1.03.

Hedge Funds Weigh In On Tevogen Bio

Several hedge funds and other institutional investors have recently modified their holdings of TVGN. Bridgeway Capital Management LLC boosted its holdings in shares of Tevogen Bio by 66.7% during the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after purchasing an additional 33,000 shares during the period. Goldman Sachs Group Inc. increased its holdings in Tevogen Bio by 126.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after purchasing an additional 152,572 shares during the period. Finally, Deutsche Bank AG increased its holdings in Tevogen Bio by 304.1% during the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after purchasing an additional 130,738 shares during the period.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.